High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. At least 6.5 x 109 mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cryopreserved, and returned intravenously following CBV administration. Three patients had an early death 2, 22, and 25 days after PSCT. The actuarial event-free survival for these 56 patients at 3 years was 37% and was as least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). CBV and PSCT for patients with relapsed Hodgkin's disease who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival.

Original languageEnglish (US)
Pages (from-to)2322-2325
Number of pages4
JournalBlood
Volume77
Issue number11
StatePublished - Jan 1 1991

Fingerprint

Peripheral Blood Stem Cell Transplantation
Carmustine
Etoposide
Stem cells
Hodgkin Disease
Cyclophosphamide
Bone
Disease-Free Survival
Bone Marrow
Tumors
Blood
Autologous Transplantation
Neoplasm Metastasis
Bone Marrow Transplantation

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

@article{1f65586f780e41b990a6b3474e2f3216,
title = "High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease",
abstract = "Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. At least 6.5 x 109 mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cryopreserved, and returned intravenously following CBV administration. Three patients had an early death 2, 22, and 25 days after PSCT. The actuarial event-free survival for these 56 patients at 3 years was 37{\%} and was as least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47{\%}, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27{\%} (P = .02). CBV and PSCT for patients with relapsed Hodgkin's disease who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival.",
author = "Anne Kessinger and Bierman, {Philip Jay} and Vose, {Julie Marie} and Armitage, {James Olen}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "77",
pages = "2322--2325",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease

AU - Kessinger, Anne

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. At least 6.5 x 109 mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cryopreserved, and returned intravenously following CBV administration. Three patients had an early death 2, 22, and 25 days after PSCT. The actuarial event-free survival for these 56 patients at 3 years was 37% and was as least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). CBV and PSCT for patients with relapsed Hodgkin's disease who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival.

AB - Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. At least 6.5 x 109 mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cryopreserved, and returned intravenously following CBV administration. Three patients had an early death 2, 22, and 25 days after PSCT. The actuarial event-free survival for these 56 patients at 3 years was 37% and was as least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). CBV and PSCT for patients with relapsed Hodgkin's disease who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival.

UR - http://www.scopus.com/inward/record.url?scp=0025912707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025912707&partnerID=8YFLogxK

M3 - Article

C2 - 1674890

AN - SCOPUS:0025912707

VL - 77

SP - 2322

EP - 2325

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -